BRAF and neoplasm: We included BRAF V600E mutation, which is the most representative molecular signature in PTC, as a variable in this study and revealed similar results as once widely reported: BRAF V600E mutation occupied up to 2/3 of all cases and is of great potentials in predicting tumor recurrence (18).